Showing results (1521-1530 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|April 14, 2023
Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patientsTakehiro Tozuka, Noriko Yanagitani, Hiroshi Yoshida, et al.
Investigational New Drugs|May 2, 2023
Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trialsXiaoli Li, Yuyan Liu, Minhui Zhu, et al.
Investigational New Drugs|May 10, 2023
Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibit moderate effect on normal stem cells growthArshak R Alexanian, Heidi Marie Stoellinger, Virginea de Araujo Farias, et al.
Investigational New Drugs|October 31, 2012
Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphomaHee Kyung Ahn, Seok Jin Kim, Deok Won Hwang, et al.
Investigational New Drugs|November 17, 2012
Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1Erika Rimondi, Paola Secchiero, Elisabetta Melloni, et al.
Investigational New Drugs|June 20, 2014
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancerEmiliano Calvo, Victor J Chen, Mark Marshall, et al.
Investigational New Drugs|May 31, 2014
In vitro 3D colon tumor penetrability of SRJ09, a new anti-cancer andrographolide analogCharng Choon Wong, Nagarajan Periasamy, Sreenivasa Rao Sagineedu, et al.
Investigational New Drugs|April 8, 2021
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancerFilip Janku, Patricia LoRusso, Aaron S Mansfield, et al.
Investigational New Drugs|April 8, 2021
Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomesMasahide Fukudo, Keiko Asai, Chikayoshi Tani, et al.
Investigational New Drugs|August 25, 2020
Crizotinib induced antitumor activity and synergized with chemotherapy and hormonal drugs in breast cancer cells via downregulating MET and estrogen receptor levelsNehad M Ayoub, Dalia R Ibrahim, Amer E Alkhalifa, et al.
Pageof 372